Skip to Main Content

The US Supreme Court may have declined to hear a case over a key rule involving the sale of biosimilars, but some attorneys said the court may review yet another similar case soon, especially since the US Solicitor General urged the justices to do so.


Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!